



Cascadian Therapeutics
Investor Relations Department
2601 4th Avenue, Suite 500
Seattle, WA 98121
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: CASC

| | |
|---------------|----------------------------|
| Last Trade: | 3.87 |
| Trade Time: | 4:00 PM ET Dec 11, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 3.18 - 6.13 |
| Volume | 38 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

We are committed to serving the best interests of our shareholders. If you require assistance or have questions regarding the key shareholder information and financial reports available here please [contact us](#).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Dec 7, 2017

[Prolonged Progression-Free Survival Reinforces Tucatinib's Potential for Patients with Advanced HER2+ Metastatic Breast Cancer](#)

Nov 8, 2017

[Cascadian Therapeutics Reports Third Quarter 2017 Financial Results](#)

Nov 1, 2017

[Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017](#)

Oct 24, 2017

[Cascadian Therapeutics to Participate in Panel Discussions at Two Conferences in November](#)

Sep 27, 2017

[Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 9, 2017

[Annual Report \(10-K\)](#)

Apr 26, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 8, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)